Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947 is registered in ClinicalTrials.gov with Poseida Therapeutics, Inc. as lead sponsor.

NCT NCT04249947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04249947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Lead sponsor
Poseida Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2020
Completion date
September 30, 2024
Enrollment
40 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acinic cell tumor, adenoid cystic carcinoma, genital neoplasms, male, metastatic castration-resistant prostate cancer, mucoepidermoid carcinoma, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, prostate, prostate cancer, prostatic disease, prostatic neoplasms, prostatic neoplasms, castration-resistant, salivary duct carcinoma, salivary gland cancer, salivary gland tumor, urogenital neoplasms